Enhancement of the Protective Efficacy of a ROP18 Vaccine Against Chronic Toxoplasmosis by Nasal Route

Overview

Journal Med Microbiol Immunol

Specialty Allergy & Immunology

Date 2016 Oct 21

PMID 27757545

Citations 11

Authors

Imran Rashid

Nathalie Moire

Bruno Heraut

Isabelle Dimier-Poisson

Marie-Noelle Mevelec

Affiliations

Soon will be listed here.

Abstract

Infection with the parasite Toxoplasma gondii causes serious public health problems and is of great economic importance worldwide. No vaccine is currently available, so the design of efficient vaccine strategies is still a topical question. In this study, we evaluated the immunoprophylactic potential of a T. gondii virulence factor, the rhoptry kinase ROP18, in a mouse model of chronic toxoplasmosis: first using a recombinant protein produced in Schneider insect cells adjuvanted with poly I:C emulsified in Montanide SV71 by a parenteral route or adjuvanted with cholera toxin by the nasal route and second using a DNA plasmid encoding ROP18 adjuvanted with GM-CSF ± IL-12 DNA. If both intranasal and subcutaneous recombinant ROP18 immunizations induced predominantly anti-ROP18 IgG1 antibodies and generated a mixed systemic Th1-/Th2-type cellular immune response characterized by the production of IFN-γ, IL-2, Il-10 and IL-5, only intranasal vaccination induced a mucosal (IgA) humoral response in intestinal washes associated with a significant brain cyst reduction (50 %) after oral challenge with T. gondii cysts. DNA immunization induced antibodies and redirected the cellular immune response toward a Th1-type response (production of IFN-γ and IL-2) but did not confer protection. These results suggest that ROP18 could be a component of a subunit vaccine against toxoplasmosis and that strategies designed to enhance mucosal protective immune responses could lead to more encouraging results.

Citing Articles

Evaluation of protective immune responses induced by DNA vaccines encoding EgM123 protein in Beagle dogs.

Wang N, Xian J, Zhao P, Zhao W, Pu N, Jia X Front Vet Sci. 2024; 11:1444741.

PMID: 39386253 PMC: 11462624. DOI: 10.3389/fvets.2024.1444741.

Intranasal immunisation with recombinant Toxoplasma gondii uridine phosphorylase confers resistance against acute toxoplasmosis in mice.

Yin L, Ren Y, You Y, Yang Y, Wang Z, Wang H Parasite. 2023; 30:46.

PMID: 37921620 PMC: 10624161. DOI: 10.1051/parasite/2023047.

Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles Expressing Rhoptry Protein 18.

Yoon K, Chu K, Kang H, Kim M, Eom G, Mao J Vaccines (Basel). 2022; 10(10).

PMID: 36298453 PMC: 9609909. DOI: 10.3390/vaccines10101588.

Toxoplasma gondii vaccine candidates: a concise review.

Javadi Mamaghani A, Fathollahi A, Arab-Mazar Z, Kohansal K, Fathollahi M, Spotin A Ir J Med Sci. 2022; 192(1):231-261.

PMID: 35394635 PMC: 8992420. DOI: 10.1007/s11845-022-02998-9.

Immune response against toxoplasmosis-some recent updates RH: immune response.

Sana M, Rashid M, Rashid I, Akbar H, Gomez-Marin J, Dimier-Poisson I Int J Immunopathol Pharmacol. 2022; 36:3946320221078436.

PMID: 35227108 PMC: 8891885. DOI: 10.1177/03946320221078436.

References

Dimier-Poisson I, Carpentier R, Nguyen T, Dahmani F, Ducournau C, Betbeder D . Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection. Biomaterials. 2015; 50:164-75. DOI: 10.1016/j.biomaterials.2015.01.056. View

Xue M, He S, Zhang J, Cui Y, Yao Y, Wang H . Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine. Exp Parasitol. 2008; 119(3):352-7. DOI: 10.1016/j.exppara.2008.03.005. View

Appaiahgari M, Vrati S . Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther. 2014; 15(3):337-51. DOI: 10.1517/14712598.2015.993374. View

Jongert E, Lemiere A, Van Ginderachter J, De Craeye S, Huygen K, DSouza S . Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. Vaccine. 2010; 28(13):2556-64. DOI: 10.1016/j.vaccine.2010.01.031. View

Denkers E, Gazzinelli R . Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev. 1998; 11(4):569-88. PMC: 88897. DOI: 10.1128/CMR.11.4.569. View

Ismael A, Hedhli D, Cerede O, Lebrun M, Dimier-Poisson I, Mevelec M . Further analysis of protection induced by the MIC3 DNA vaccine against T. gondii: CD4 and CD8 T cells are the major effectors of the MIC3 DNA vaccine-induced protection, both Lectin-like and EGF-like domains of MIC3 conferred protection. Vaccine. 2009; 27(22):2959-66. DOI: 10.1016/j.vaccine.2009.02.107. View

Liu M . DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011; 239(1):62-84. DOI: 10.1111/j.1600-065X.2010.00980.x. View

Suzuki Y, Remington J . The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice. J Immunol. 1990; 144(5):1954-6. View

Verma R, Khanna P . Development of Toxoplasma gondii vaccine: A global challenge. Hum Vaccin Immunother. 2012; 9(2):291-3. PMC: 3859749. DOI: 10.4161/hv.22474. View

10.

Aucouturier J, Ascarateil S, Dupuis L . The use of oil adjuvants in therapeutic vaccines. Vaccine. 2006; 24 Suppl 2:S2-44-5. DOI: 10.1016/j.vaccine.2005.01.116. View

11.

Jongert E, Roberts C, Gargano N, Forster-Waldl E, Forster-Wald E, Petersen E . Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz. 2009; 104(2):252-66. DOI: 10.1590/s0074-02762009000200019. View

12.

Robert-Gangneux F, Darde M . Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012; 25(2):264-96. PMC: 3346298. DOI: 10.1128/CMR.05013-11. View

13.

Montoya J, Remington J . Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008; 47(4):554-66. DOI: 10.1086/590149. View

14.

Grzybowski M, Dziadek B, Gatkowska J, Dzitko K, Dlugonska H . Towards vaccine against toxoplasmosis: evaluation of the immunogenic and protective activity of recombinant ROP5 and ROP18 Toxoplasma gondii proteins. Parasitol Res. 2015; 114(12):4553-63. DOI: 10.1007/s00436-015-4701-y. View

15.

El Hajj H, Lebrun M, Arold S, Vial H, Labesse G, Dubremetz J . ROP18 is a rhoptry kinase controlling the intracellular proliferation of Toxoplasma gondii. PLoS Pathog. 2007; 3(2):e14. PMC: 1797617. DOI: 10.1371/journal.ppat.0030014. View

16.

Debard N, Buzoni-Gatel D, Bout D . Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect Immun. 1996; 64(6):2158-66. PMC: 174050. DOI: 10.1128/iai.64.6.2158-2166.1996. View

17.

Khaznadji E, Boulard C, Moire N . Expression of functional hypodermin A, a serine protease from Hypoderma lineatum (Diptera, Oestridae), in Schneider 2 cells. Exp Parasitol. 2003; 104(1-2):33-9. DOI: 10.1016/s0014-4894(03)00115-2. View

18.

Li X, Wang X, Xia L, Weng Y, Hernandez J, Tu L . Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice. BMC Infect Dis. 2015; 15:114. PMC: 4397727. DOI: 10.1186/s12879-015-0815-1. View

19.

Cui Y, He S, Xue M, Zhang J, Wang H, Yao Y . Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice. Parasite Immunol. 2008; 30(5):309-13. DOI: 10.1111/j.1365-3024.2008.01025.x. View

20.

Alaganan A, Fentress S, Tang K, Wang Q, Sibley L . Toxoplasma GRA7 effector increases turnover of immunity-related GTPases and contributes to acute virulence in the mouse. Proc Natl Acad Sci U S A. 2014; 111(3):1126-31. PMC: 3903209. DOI: 10.1073/pnas.1313501111. View